SCHEDULE: Adage Capital Management Discloses 4.54% Stake in Relmada Therapeutics

Adage Capital Management, L.P. and its affiliates have reported beneficial ownership of 4,763,158 shares, representing 4.54% of the outstanding common stock of Relmada Therapeutics, Inc.

Summary

• Adage Capital Management, L.P. (ACM), along with its associated entities and individuals Robert Atchinson and Phillip Gross, has filed a Schedule 13G.
• This filing indicates beneficial ownership of 4,763,158 shares of Relmada Therapeutics, Inc. common stock.
• This holding represents 4.54% of the company's outstanding common stock as of March 16, 2026.
• The filing is an amendment (Amendment No. 1) and was made on March 31, 2026, concerning an event requiring filing on that date.
• The reporting persons are classified as investment advisers (IA) and investment companies (IN).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant investment by a known institutional manager, suggesting confidence, but provides no operational or financial performance data.

Positives

• Adage Capital Management, L.P. has taken a significant stake, indicating confidence in Relmada Therapeutics' future prospects.
• The 4.54% ownership stake suggests a substantial investment by a recognized investment manager.

Negatives

• The filing does not contain any negative financial results or operational challenges.
• No specific negative forward-looking statements are present in this disclosure.

Risks

• The filing does not explicitly detail any current issues or potential future challenges for Relmada Therapeutics.
• As a Schedule 13G filing, it primarily reports ownership and does not typically include risk factor disclosures.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or specific guidance regarding the company's future performance.

Management Comments

• The filing includes a certification stating that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies, indicating a passive investment approach rather than an attempt to gain control. This filing by Adage Capital Management suggests a notable investment in the biotechnology sector, specifically within Relmada Therapeutics.

Stakeholder Impact

• Shareholders may view the increased institutional ownership as a positive signal of confidence in the company's long-term value.
• The investment by Adage Capital Management could potentially attract further investor interest in Relmada Therapeutics.

Next Steps

• The reporting persons will continue to hold their shares in Relmada Therapeutics, Inc.
• Further filings may be required if ownership levels change significantly.

Key Dates

Keywords

Relmada Therapeutics, Schedule 13G, Adage Capital Management, SEC Filing, Beneficial Ownership, Common Stock, Investment Management, Phillip Gross, Robert Atchinson